Track market-moving stories before they get noisy

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer.

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts June 25, 2026 07:30 ET  | Source: OptimizeRx Corporation

WALTHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded within both demand-side platforms (DSPs) and agency media planning platforms.

NLAB combines real-world evidence with proprietary data from OptimizeRx’s best-in-class EHR network so life sciences companies and agency marketers can better create and manage custom HCP audiences within the media planning and buying platforms they already use. By connecting audience intelligence to point of care reach, NLAB helps identify the right providers and activate messages in the clinical workflows where prescribing decisions are made.

With NLAB, marketers can:

Build and refine custom NPI lists without code or analyst support, and without relying on predefined segment matchesView, rank, and filter matching HCP profile details, including specialty, patient volumes, prescribing behavior, and moreUnderstand NPI-level reach and accessibility across media channels (programmatic, social, EHR, field force)Identify which HCPs are most likely to engage with, and take action based on, EHR advertising This technology launch builds on OptimizeRx’s prior announcement opening programmatic access to its authenticated EHR inventory and expands the Company’s role as an infrastructure partner for life sciences manufacturers, agencies, and DSPs serving the healthcare ecosystem.

“Healthcare marketers need a faster way to build audiences that reflect the strategy behind each campaign, without relying on ‘good enough’ pre-built segments,” said Mike Rousselle, Chief AI Officer at OptimizeRx. “By embedding this capability into DSP and media planning platforms, we are giving pharma and agency teams an easier, more intuitive way to build custom HCP audiences, while helping DSPs bring stronger healthcare intelligence into the workflows their clients already use.”

“DSPs represent an important growth channel for OptimizeRx as more healthcare media investment moves through programmatic platforms,” said Stephen Silvestro, CEO of OptimizeRx. “By embedding audience intelligence alongside our EHR inventory directly into DSP workflows, we can help our partners deliver more differentiated value to pharma and agency clients while creating new recurring revenue streams for our business.”

NLAB will be available for platform integration from August 2026, and can be bundled with the integration of OptimizeRx’s authenticated point of care inventory. To inquire about integrating OptimizeRx audience building tools into your programmatic or media planning platform, contact Louis Trivento, SVP Strategic Partnerships, [email protected].

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life sciences brands connect with patients and healthcare providers. We combine innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "enabling", "activate”, “access”, "can", "embed", "will", "expands", "helps" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of OptimizeRx to embed NLAB technology into DSPs and media planning platforms, the Company’s expansion as an infrastructure partner to the life sciences industry, the ability of healthcare marketers to easily and more intuitively build custom HCP audiences and activate media more efficiently, helping DSPs bring stronger healthcare intelligence into their clients’ workflows, a DSP’s ability to offer differentiated value to its life sciences clients, and the timely availability of NLAB for platform integration. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Jennifer Dinkel, SVP Marketing
[email protected]

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]

Press Inquiries
Matter Communications
[email protected]

Partnership Inquires
Louis Trivento, SVP Strategic Partnerships
[email protected]

April 28, 2026 08:00 ET  | Source: OptimizeRx Corporation

WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-877-407-9716International: 1-201-493-6779Conference ID: 13760191Call me™ Link: https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1760247&tp_key=80ee98d522
Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the investors section of the OptimizeRx website at http://www.optimizerx.com/investors.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]    

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One stock to keep an eye on is OptimizeRx (OPRX - Free Report) . OPRX is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value.

Investors should also note that OPRX holds a PEG ratio of 0.96. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. OPRX's PEG compares to its industry's average PEG of 1.43. Over the past 52 weeks, OPRX's PEG has been as high as 1.13 and as low as 0.33, with a median of 0.76.

Another notable valuation metric for OPRX is its P/B ratio of 2.83. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 6.51. Over the past year, OPRX's P/B has been as high as 2.94 and as low as 0.61, with a median of 1.25.

Value investors will likely look at more than just these metrics, but the above data helps show that OptimizeRx is likely undervalued currently. And when considering the strength of its earnings outlook, OPRX sticks out as one of the market's strongest value stocks.

Key Takeaways OptimizeRx is set to post Q1 results on May 12, with revenues projected to fall 15.9% year over year.OPRX cites weaker managed services demand and conservative pharma spending as key headwinds.The company expects 2026 growth to be backloaded, with stronger performance in the second half. OptimizeRx Corporation (OPRX - Free Report) will report its first-quarter 2026 results on May 12, after the market close.

The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at 1 cent, compared with 8 cents reported in the prior-year quarter. The estimate has deteriorated from 2 cents per share over the past 60 days.

Image Source: Zacks Investment Research

The consensus estimate for total revenues is pinned at $18.45 million, down 15.9% year over year.

OPRX’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 390.29%.

What Our Model Predicts for OPRX’s Q1Our proven model does not predict an earnings beat for OPRX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

OPRX has an Earnings ESP of -500.00% and a Zacks Rank #3.

You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Factors to Focus on Ahead of OPRX’s Q1 EarningsManagement has flagged a slower start to 2026, caused by macro and industry-specific dynamics. Softness in contracted revenues, linked to a broader market shift away from managed services, is an overhang. Management noted that the first half of 2025 saw $9 million higher managed services revenues, which are not expected to repeat this time around.

Moreover, volatility is increasing as pharmaceutical clients adopt a more conservative spending approach amid Most Favored Nation (“MFN”) pricing dynamics.

Management has lowered the revenue outlook for 2026 to $109-$114 million compared with the $118-$124 million provided at the end of the third quarter of 2025. The year is expected to be backloaded, with first-half revenues at 40% and 60% expected for the second half. As a result, the first-quarter performance is expected to have reflected these headwinds.

Coming to margins, while gross margin was 74.8% in the fourth quarter of 2025, OptimizeRx has guided for moderation in 2026, with gross margins expected in the mid-60% range due to normalization in channel mix. The company reiterated its focus on adjusted EBITDA, guiding $21-$25 million for 2026. This is more than the previously mentioned $19-$22 million. In addition to a fixed cost base and scalable operating model, EBITDA is gaining from cost discipline measures (post the Medicx buyout).

Moreover, OptimizeRx emphasized that the pharma marketing spend headwinds appear temporary. Management noted that the company continues to see strong engagement across its network and is confident that the demand trends will cushion the business. It expects normalization over the coming quarters.

Additionally, the expanding adoption of OPRX’s Dynamic Audience Activation Platform (“DAAP”) bodes well. The DAAP platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences across a strong network of clinical and personal platforms.

The company has also been seeing momentum across both established pharmaceutical clients and mid-tier/long-tail life science customers.

On the last earnings call, OptimizeRx addressed AI concerns, positioning it as a tailwind rather than a disruption risk, highlighting that AI is expected to free up marketing budgets, which are usually allocated up to 50% to content creation. These could be reallocated toward marketing execution and audience reach, areas where OptimizeRx shines, as highlighted by management.

OPRX Stock PlungesShares of OptimizeRx have lost 60.8% in the past six months compared with the Zacks Computer Software industry’s decline of 19.1%.

Price Performance
Image Source: Zacks Investment Research

Peers such as GoodRx Holdings, Inc. (GDRX - Free Report) , Phreesia (PHR - Free Report) and Doximity (DOCS - Free Report) have declined 16%, 57.9% and 51.1%, respectively.

GoodRx Holdings is another digital healthcare company focused on medication savings in the United States and used by nearly 25 million consumers. Doximity is a top-tier U.S. medical network, used by more than 85% of physicians and a majority of NPs and PAs. Phreesia offers an automated platform for healthcare organizations to manage patient intake.

Key Valuation Metric for OPRXOPRX is trading at a forward 12-month price-to-sales ratio of 1.05, a discount compared with the Zacks Computer Software industry’s 7.05 and the Zacks Computer & Technology sector’s 6.78.

Image Source: Zacks Investment Research

In comparison, DOCS, GDRX and PHR are trading at multiples of 6.81X, 1.12X and 1.1X, respectively.

What to Do With OPRX Stock Before Q1Reduced near-term visibility and management’s expectation of a backloaded year, OPRX appears vulnerable to near-term volatility. On the flip side, strong EBITDA guidance and long-term platform traction provide a strong underlying narrative.

Overall, existing investors could wait for commentary at the upcoming earnings call, while new investors would be better off waiting for a favorable entry point. 

Key Takeaways OptimizeRx launched a DSP integration for direct access to authenticated EHR ad inventory.OPRX aims to expand point-of-care targeting within broader omnichannel ad strategies.OptimizeRx sees momentum in its Dynamic Audience Activation Platform and pharma clients. OptimizeRx Corporation (OPRX - Free Report) has launched a new programmatic connection point between its proprietary electronic health record (EHR) network and demand-side platforms (DSPs), enabling life sciences marketers to access authenticated EHR advertising inventory directly through existing programmatic buying workflows.

The launch marks a significant expansion of OptimizeRx’s capabilities, allowing media buyers to combine the efficiency and scalability of programmatic advertising with precise targeting at the point of care, while enabling healthcare professionals to receive relevant brand messaging directly within their clinical workflow at key decision-making moments. Through the new integration, advertisers can now activate EHR campaigns more quickly, manage campaign reach and frequency independently, and seamlessly include EHR placements within broader omnichannel marketing strategies.

The company stated that the initiative also opens OptimizeRx to the broader programmatic advertising ecosystem, which accounts for nearly 90% of total U.S. digital display advertising spend across industries. By integrating its EHR network with DSPs, OptimizeRx aims to provide marketers with authenticated, bot-free inventory that reaches healthcare professionals directly within their clinical workflow.

Management highlighted that the launch addresses a longstanding challenge for life sciences advertisers, who previously had to choose between managed EHR campaigns offering direct clinical engagement and programmatic buying options that often lacked verified access to real-time healthcare decision-making moments. Management also stated that the new offering expands access to critical healthcare engagement opportunities while helping DSPs strengthen their value proposition in the life sciences sector.

OptimizeRx added that DSP partners will now be able to differentiate themselves by offering premium point-of-care advertising inventory within their native platforms. The company believes the integration can help DSPs capture a larger share of the more than $19 billion pharmaceutical digital advertising market by meeting growing demand for scalable and measurable healthcare-focused advertising solutions.

Additionally, the expanding adoption of OPRX’s Dynamic Audience Activation Platform bodes well. The company has also been seeing momentum across both established pharmaceutical clients and mid-tier/long-tail life science customers.

OptimizeRx is slated to report first-quarter 2026 results on May 12, after market close.

Let’s Look at the Strategies of CompetitorsDoximity, Inc. (DOCS - Free Report) continues to expand beyond its core pharma marketing business into hiring, telehealth and workflow solutions, broadening its monetization opportunities across a large U.S. TAM while deepening engagement with health systems and pharma clients. Growth is being supported by strong adoption of high-margin products like point-of-care and formulary alerts, increasing workflow usage among prescribers and rising cross-sell opportunities. At the same time, the company’s AI-driven offerings, including DocsGPT, are enhancing physician engagement and platform stickiness, with growing adoption across clinicians and enterprise health systems, positioning DOCS to strengthen its long-term competitive advantage and future monetization potential.

Veeva Systems Inc. (VEEV - Free Report) remains well-positioned as a long-term winner in life sciences digitalization, supported by strong execution, deep customer trust and a broad, integrated product portfolio. Vault CRM adoption continues to scale, while growth is increasingly driven by newer R&D solutions like RTSM, Safety and LIMS alongside strong Crossix performance. The company is also investing steadily in innovation, embedding AI across applications to enhance automation and long-term value creation. The company is seeing expanding adoption across multiple applications during large migrations, with customers increasingly adding solutions like Network, OpenData, Service Center and Campaign Manager alongside core deployments.

OPRX Price Performance, Valuation & EstimatesShares of OptimizeRx have lost 29% in the past three months against the Computer Software industry’s growth of 4.2%.

Image Source: Zacks Investment Research

Regarding the forward 12-month price/sales ratio, OPRX is trading at 1.01, lower than the sector’s multiple of 7.02.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2027 has been revised downward over the past 60 days.

Image Source: Zacks Investment Research

OPRX currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

OptimizeRx Corp. (OPRX - Free Report) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +1,300.00%. A quarter ago, it was expected that this company would post earnings of $0.23 per share when it actually produced earnings of $0.51, delivering a surprise of +121.74%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

OptimizeRx, which belongs to the Zacks Computer - Software industry, posted revenues of $19.84 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 7.59%. This compares to year-ago revenues of $21.93 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

OptimizeRx shares have lost about 49.4% since the beginning of the year versus the S&P 500's gain of 8.3%.

What's Next for OptimizeRx?While OptimizeRx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for OptimizeRx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.15 on $24.63 million in revenues for the coming quarter and $0.93 on $112.39 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computer - Software is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Descartes Systems (DSGX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended April 2026. The results are expected to be released on June 3.

This logistics provider is expected to post quarterly earnings of $0.53 per share in its upcoming report, which represents a year-over-year change of +29.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Descartes Systems' revenues are expected to be $191.7 million, up 13.6% from the year-ago quarter.

OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics and other macroeconomic pressures.

Chief Executive Officer Steve Silvestro said revenue for the quarter was $19.8 million and adjusted EBITDA was $3.3 million. He characterized the quarter as a “solid start to the year,” but said the healthcare technology operating environment remains in flux.

Get OptimizeRx alerts:

“We’re seeing ongoing softness in our contracted revenue base relative to prior year levels,” Silvestro said, pointing to “short to intermediate term disruption” from last year’s most-favored-nation pricing dynamics, along with broader macroeconomic factors. He said those factors have led to “more cautious budget allocations, contract durations, and in some cases, the delaying of campaign timing and scope.”

Despite those headwinds, Silvestro said the company does not believe the pressures will endure, adding that OptimizeRx has made progress with several large manufacturers in restoring spending levels.

Revenue Declines, Profitability Improves Chief Financial and Strategic Officer Edward Stelmakh said first-quarter revenue fell 10% to $19.8 million from $21.9 million in the same period of 2025. He attributed the decline in part to lower-margin managed services revenue, a revenue reduction on a major client account, and more cautious customer budget allocations and shorter program commitments.

Expenses decreased by $4.6 million year over year, which Stelmakh said was primarily due to lower cost of revenue and general and administrative expenses. He said the lower cost of revenue reflected a more favorable product mix, including no direct-to-consumer managed services revenue in the quarter, as well as favorable channel partner mix.

The company’s GAAP net loss narrowed to $0.5 million, or $0.03 per basic and diluted share, compared with a net loss of $2.2 million, or $0.12 per basic and diluted share, in the year-earlier quarter. On a non-GAAP basis, net income rose to $2.7 million, or $0.14 per diluted share, from $1.5 million, or $0.08 per diluted share, a year earlier. Adjusted EBITDA increased to $3.3 million from $1.5 million in the first quarter of 2025.

Operating cash flow was negative $0.5 million, which Stelmakh said was primarily tied to payouts of 2025 bonuses and fourth-quarter 2025 sales commissions during the first quarter. The company ended the quarter with $20.2 million in cash, down from $23.4 million at the end of 2025, and debt of $23.6 million after paying down $2.7 million of principal during the quarter.

Guidance Lowered for Revenue, EBITDA Outlook Maintained OptimizeRx now expects full-year 2026 revenue of $95 million to $100 million. Management maintained its adjusted EBITDA guidance of $21 million to $25 million and continued to expect revenue to be weighted toward the second half of the year at roughly a 40/60 split.

Silvestro said the revised revenue outlook reflects reduced visibility for the full year, even as the company sees growth in certain parts of the business. Stelmakh said the company expects gross margins to normalize in the high-60% range for the full year, citing margin optimization efforts implemented over the last 12 months.

Silvestro also said the company has taken actions to align its cost structure with the current environment, including prioritizing strategic investments, reducing discretionary spending, deploying new agentic technology tools internally and leveraging the scalability of its largely fixed-cost platform. He said those actions are expected to reduce cash operating expenses by approximately $3 million on an annualized basis, including about $1 million of benefit in 2026, excluding severance-related impacts.

DAAP and Subscription Revenue Continue to Grow Management highlighted growth in OptimizeRx’s AI-enabled DAAP solution, which Silvestro said grew 60% in the first quarter. DAAP subscription revenue rose 45%, according to Silvestro, who said the company continues to shift more revenue toward subscription-based models to improve visibility and predictability over time.

Silvestro said one top pharmaceutical client has expanded its use of point-of-prescribe solutions across multiple oncology brands, moving from targeted engagement within specific indications to a broader multi-brand deployment. He said similar momentum is emerging in med tech, where pilot programs are expanding into multimillion-dollar engagements.

Stelmakh said average revenue per top 20 pharmaceutical manufacturer was approximately $2.8 million, with those top 20 companies representing 52% of first-quarter revenue. Net revenue retention remained at 110%, and revenue per full-time employee rose to $801,000 from $710,000 in the first quarter of 2025.

Programmatic Access Seen as Long-Term Growth Opportunity Silvestro said OptimizeRx is enabling demand-side platforms that control more than 80% of digital promotional dollars to connect directly into its proprietary electronic health record network. He described the move as a significant expansion of the company’s platform and go-to-market strategy.

According to Silvestro, the company currently uses less than 10% of available inventory across its network through traditional healthcare provider marketing initiatives. He said programmatic activation could increase utilization over time and potentially become comparable in size to the current healthcare provider business over the long term.

In response to an analyst question, Silvestro said the company expects early revenue from the DSP connections later in the second half of 2026, with more meaningful flow during the 2027 renewal cycle. He declined to provide revenue projections, saying it was too early to quantify the opportunity.

Management Points to One Major Client as Near-Term Pressure During the question-and-answer session, Silvestro said much of the reduced visibility is tied to shorter contract duration and disruption at one larger client. He said contracted revenue remained about 15% to 20% below prior-year levels, similar to what the company had described on its previous earnings call.

Silvestro said customers are continuing to renew, but shorter commitments require more frequent renewals and reduce visibility. He also acknowledged that OptimizeRx “didn’t execute well” in the affected major account, while saying the company has had constructive conversations with that client’s leadership team and has a plan to get the relationship back on track.

When asked whether the disruption could persist into 2027, Silvestro said management views it as contained to 2026. “There’s nothing mechanical wrong in any of these businesses, and certainly in our business,” he said, adding that the company could see buying from the affected clients later in the third quarter or fourth quarter.

Subsequent to the quarter, OptimizeRx refinanced its term loan with Blue Torch Capital through Fifth Third Bank. Stelmakh said the new arrangement includes a fully drawn $25 million term loan and access to a $10 million revolver. The interest rate on the term loan is SOFR plus 2.25%, compared with SOFR plus 8.5% under the prior facility, representing approximately $1.5 million in annual interest expense savings.

Silvestro closed the call by reiterating confidence in the company’s long-term opportunity, citing the shift in life sciences toward digital, data-driven engagement and the company’s focus on DAAP utilization, subscription revenue and sustainable profitable growth.

About OptimizeRx NASDAQ: OPRXOptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in OptimizeRx Right Now?Before you consider OptimizeRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.

While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Key Takeaways OptimizeRx launched a DSP connection to expand EHR ad access through programmatic workflows.OPRX said DSPs controlling 80% of healthcare ad spending can now access its EHR network.OPRX cuts 2026 revenue guidance to $95M-$100M amid pricing pressure and delayed campaigns. Healthcare marketing is evolving rapidly as pharmaceutical companies look for smarter, more measurable ways to engage both healthcare professionals (HCPs) and patients. In this transformation, OptimizeRx Corporation (OPRX - Free Report) is positioning itself as a major player by expanding its digital advertising capabilities through deeper integration with Demand-Side Platforms (DSPs). This move is likely to broaden the company’s revenue opportunity, strengthen its competitive positioning and improve long-term growth visibility in the healthcare digital engagement market.

It recently launched a new programmatic connection point between its proprietary electronic health record (EHR) network and DSPs, enabling life sciences marketers to access authenticated EHR advertising inventory directly through existing programmatic buying workflows. OptimizeRx is enabling major DSPs, which control more than 80% of digital healthcare ad spending, to access its proprietary EHR network directly. This platform expansion strengthens its go-to-market strategy, allowing media buyers to run scalable point-of-care and point-of-prescribe campaigns within existing programmatic workflows. The move positions OptimizeRx as a healthcare-focused supply-side platform and is expected to drive strong growth through 2027.

OptimizeRx estimates it currently uses less than 10% of its network inventory through traditional HCP marketing. By enabling programmatic activation — the preferred method for pharma media agencies — the company sees significant potential to increase inventory utilization over time. Management believes this channel could grow substantially and eventually match the size of its existing HCP business. Despite ongoing growth, persistent macroeconomic challenges and limited full-year visibility, OPRX lowered its 2026 outlook, now expecting revenue between $95 million and $100 million. This is the second reduction from its initial 2026 guidance of $118-$124 million issued after third-quarter 2025 results.

OPRX continues to face weakness in its contracted revenue base as healthcare industry pricing pressures and broader macroeconomic uncertainty lead to cautious spending, shorter contract durations and delayed campaign activity. However, management emphasized that these issues are not structural threats to the company’s long-term business model. It noted that customer engagement remains healthy in areas less affected by MFN-related disruptions, especially among mid-tier and emerging pharmaceutical clients, suggesting demand for digital healthcare engagement tools remains intact despite temporary market caution.

How Does OPRX Stack Up Against Competitive Pressures?Veeva Systems (VEEV - Free Report) ended fiscal 2026 with record revenue and operating income, surpassing its $3 billion run-rate target and reaffirming plans for CRM to contribute roughly 10% of revenue by 2030. Ongoing innovation, strong customer trust and AI-driven product expansion in R&D and services support growth, while guidance signals confidence despite macro and migration risks. In March, Veeva acquired Ostro, an AI-driven engagement platform that delivers real-time, compliant answers to patients and doctors via brand websites. Using conversational AI and approved content, it provides trusted responses without hallucinations while generating insights to help life sciences companies improve reach and engagement.

Doximity (DOCS - Free Report) remains a top clinician platform, with network scale and subscription revenue supporting durable profitability. Its early integration of generative AI through Doximity GPT has accelerated product stickiness and physician utility. DOCS is scaling AI usage quickly inside its clinician workflow, which can deepen engagement and strengthen differentiation if it converts into durable products. Its client portal and multi-module campaign capabilities have deepened revenue per client, especially among the top 20 pharma customers. Integrated programs that combine content, AI-driven timing and performance data are driving increased spend. However, pharma spending uncertainty, customer concentration, AI investments and legal risks could pressure visibility, margins and sentiment.

OPRX Price Performance, Valuation & EstimatesShares of OptimizeRx have lost 34.5% in the past three months against the Computer Software industry’s growth of 9.7%.

Image Source: Zacks Investment Research

Valuation-wise, OPRX seems attractive, as suggested by the Value Score of A. Regarding the forward 12-month price/sales ratio, OPRX is trading at 0.88, lower than the industry’s multiple of 7.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2027 has been revised downward over the past 60 days.

Image Source: Zacks Investment Research

OPRX currently has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers May 21, 2026 07:30 ET  | Source: OptimizeRx Corporation

WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent, the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx’s proprietary electronic health record (EHR) network into its healthcare advertising platform.

By combining OptimizeRx’s authenticated EHR network with DeepIntent’s healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP workflows, using the same programmatic tools they already rely on for digital media buying. This collaboration also reflects the growing demand for privacy-safe advertising solutions tied to real clinical workflows.

“Our integration with DeepIntent makes validated EHR inventory easier to activate within a platform our clients already trust and value,” said Steve Silvestro, Chief Executive Officer at OptimizeRx. “As we expand programmatic access to our authenticated EHR network, our focus is helping more brands deliver measurable point of care engagement.”

Bringing Programmatic Buying into the Clinical Workflow

As healthcare marketers navigate growing signal loss, tighter privacy standards, and other limitations across traditional open-web advertising, demand is growing for more deterministic, measurable ways to reach providers at clinically relevant moments.

Building on DeepIntent’s existing point of care and omnichannel capabilities, the OptimizeRx integration enables life science marketers to:

Access OptimizeRx’s authenticated EHR inventory directly within DeepIntent’s platformExtend omnichannel campaigns into point of care environmentsReach providers closer to clinical decision momentsActivate scalable point of care campaigns with the speed, control, and flexibility of programmatic buying
DeepIntent is widely recognized for its healthcare-focused DSP capabilities, including audience targeting, activation, optimization, and measurement solutions designed specifically for life sciences brands. Adding reach within OptimizeRx’s proprietary EHR network helps marketers better align media activation with provider engagement across the care journey.

“We’re excited to bring OptimizeRx’s industry-leading EHR network to our established client base of pharmaceutical brands, healthcare agencies, and enterprise marketers,” said Lisa Kopp Johnson, Chief Revenue Officer, DeepIntent. “By offering scalable access to providers directly within their clinical workflows, we can help deliver more timely and relevant information that supports informed care decisions and better patient outcomes. This partnership comes as DeepIntent is building the richest marketplace of vital inventory relevant to our clients.”

Expanding Access to Point of Care Media

The DeepIntent collaboration reflects OptimizeRx’s broader strategy to expand programmatic access to its authenticated EHR network through select DSP partnerships. By opening its infrastructure to additional demand-side integrations over time, the company aims to make clinically aligned point of care media more accessible within modern healthcare advertising workflows.

Availability

OptimizeRx’s authenticated EHR network is expected to be available on the DeepIntent platform in Q3 2026. For more information about availability or to inquire about DSP integration opportunities, please contact us at https://www.optimizerx.com/contact-us.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life sciences brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. 

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. 

For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.

About DeepIntent

DeepIntent is the leading healthcare demand-side platform (DSP), purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. Trusted by the world’s top healthcare brands and their agencies, DeepIntent uniquely unites media, identity, and real-world clinical data to power privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent’s platform delivers measurable audience quality and script lift at scale. Learn more at www.deepintent.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will", "can", "activate", “access”, “expanding", "incorporate", "connecting" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the availability of OptimizeRx’s EHR inventory on the DeepIntent DSP, the growing demand for privacy-safe advertising solutions tied to real clinical workflows, the success of pharmaceutical brands to deliver measurable point of care management, the ability of healthcare marketers to activate point of care campaigns at scale, expansion of programmatic access to the Company’s EHR network, and the accessibility of clinically aligned point of care media within healthcare advertising workflows. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

OptimizeRx Contact
Jennifer Dinkel, VP Marketing 
[email protected]

OptimizeRx Investor Relations Contact
Douglas Farrell 
LifeSci Advisors, LLC 
[email protected]

OptimizeRx Press Inquiries
Matter Communications
[email protected] 

DeepIntent Press Inquiries
[email protected]

OptimizeRx Partnership Inquiries
Louis Trivento, SVP Strategic Partnerships 
[email protected] 

June 01, 2026 07:30 ET  | Source: OptimizeRx Corporation

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

Stifel 2026 Boston Cross Sector 1x1 Conference, Boston, June 2 – 3, 202646th Annual William Blair Growth Stock Conference, Chicago, June 2 – 4, 2026 Stifel 2026 Boston Cross Sector 1x1 ConferenceDate:  Tuesday, June 2, 2026 Format: 1x1 Meetings Location: InterContinental Boston   William Blair & Company’s 46th Annual Growth Stock ConferenceDate:  Wednesday, June 3, 2026 Format: 1x1 Meetings and Corporate PresentationLocation: Loews Hotel Chicago Presentation Time: 8-8:30 am CDT To request a meeting or for more details about the conferences please reach out to your institutional contact.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]